Tumor expression of Fas ligand (CD95L) and the consequences.

Walker PR; Saas P; Dietrich PY

doi:10.1016/s0952-7915(98)80225-2

Tumor expression of Fas ligand (CD95L) and the consequences.

Walker PR ¹,

Saas P ,

Dietrich PY

Affiliations

1. Laboratory of Tumour Immunology, Division of Oncology, University Hospital Geneva, 24 rue Micheli-du-Crest, CH-1211, Geneva 14, Switzerland.
Authors
Walker PR¹
(1 author)

ORCIDs linked to this article

Current Opinion in Immunology, 01 Oct 1998, 10(5):564-572
https://doi.org/10.1016/s0952-7915(98)80225-2 PMID: 9794830

Review

Abstract

Tumors of diverse origin have recently been shown to express CD95 ligand and to induce apoptosis in CD95-expressing targets in vitro; however, in vivo, enhanced tumor growth and rejection have both been observed as a consequence of either immunosuppressive or proinflammatory functions of CD95 ligand. The final in vivo outcome of CD95 ligand expression will depend upon a complex balance of interactions relevant for each tumor in its particular microenvironment.

Full text links

Read article at publisher's site: https://doi.org/10.1016/s0952-7915(98)80225-2

References

Articles referenced by this article (73)

Apoptosis by death factor.
Nagata S
Cell, (3):355-365 1997
MED: 9039262
Homeostasis and self-tolerance in the immune system: turning lymphocytes off.
Van Parijs L, Abbas AK
Science, (5361):243-248 1998
MED: 9535647
Pathways leading to cell death in T cells.
Wong B, Choi Y
Curr Opin Immunol, (3):358-364 1997
MED: 9203409
Fas ligand-induced apoptosis as a mechanism of immune privilege.
Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA
Science, (5239):1189-1192 1995
MED: 7502042
A role for CD95 ligand in preventing graft rejection.
Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC
Nature, (6550):630-632 1995
MED: 7566174
Fas ligand is positioned in mouse uterus and placenta to prevent trafficking of activated leukocytes between the mother and the conceptus.
Hunt JS, Vassmer D, Ferguson TA, Miller L
J Immunol, (9):4122-4128 1997
MED: 9126971
Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?
Saas P, Walker PR, Hahne M, Quiquerez AL, Schnuriger V, Perrin G, French L, Van Meir EG, de Tribolet N, Tschopp J, Dietrich PY
J Clin Invest, (6):1173-1178 1997
MED: 9077524
Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape.
Hahne M, Rimoldi D, Schroter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini J, Tschopp J
Science, (5291):1363-1366 1996
MED: 8910274
Gene transfer of Fas ligand induces tumor regression in vivo.
Arai H, Gordon D, Nabel EG, Nabel GJ
Proc Natl Acad Sci U S A, (25):13862-13867 1997
MED: 9391118
The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand.
O'Connell J, O'Sullivan GC, Collins JK, Shanahan F
J Exp Med, (3):1075-1082 1996
MED: 9064324

Show 10 more references (10 of 73)

Citations & impact

Impact metrics

Citations

Jump to Citations

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/35393791

Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/35393791

Article citations

Apoptosis of tumor-infiltrating T lymphocytes: a new immune checkpoint mechanism.
Zhu J, Petit PF, Van den Eynde BJ
Cancer Immunol Immunother, 68(5):835-847, 07 Nov 2018
Cited by: 63 articles | PMID: 30406374 | PMCID: PMC11028327
Review Free full text in Europe PMC
The rationale of vectored gene-fusion vaccines against cancer: evolving strategies and latest evidence.
Ragonnaud E, Holst P
Ther Adv Vaccines, 1(1):33-47, 01 May 2013
Cited by: 2 articles | PMID: 24757514 | PMCID: PMC3967669
Free full text in Europe PMC
Induction of apoptosis by laminarin, regulating the insulin-like growth factor-IR signaling pathways in HT-29 human colon cells.
Park HK, Kim IH, Kim J, Nam TJ
Int J Mol Med, 30(4):734-738, 02 Aug 2012
Cited by: 24 articles | PMID: 22859258 | PMCID: PMC3573771
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Weapons ovarian epithelial tumors may use in immune escape: an immunohistochemical correlational study.
Hasby EA
Pathol Oncol Res, 18(2):509-518, 08 Dec 2011
Cited by: 5 articles | PMID: 22161157
Toll-like receptor 4 activation in cancer progression and therapy.
Oblak A, Jerala R
Clin Dev Immunol, 2011:609579, 03 Nov 2011
Cited by: 87 articles | PMID: 22110526 | PMCID: PMC3216292
Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC

Go to all (65) article citations

Search life-sciences literature (45,103,589 articles, preprints and more)

Tumor expression of Fas ligand (CD95L) and the consequences.

Affiliations

Authors

ORCIDs linked to this article

Abstract

Full text links

References

Apoptosis by death factor.

Homeostasis and self-tolerance in the immune system: turning lymphocytes off.

Pathways leading to cell death in T cells.

Fas ligand-induced apoptosis as a mechanism of immune privilege.

A role for CD95 ligand in preventing graft rejection.

Fas ligand is positioned in mouse uterus and placenta to prevent trafficking of activated leukocytes between the mother and the conceptus.

Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?

Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape.

Gene transfer of Fas ligand induces tumor regression in vivo.

The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand.

Citations & impact

Impact metrics

Citations of article over time

Alternative metrics

Article citations

Apoptosis of tumor-infiltrating T lymphocytes: a new immune checkpoint mechanism.

The rationale of vectored gene-fusion vaccines against cancer: evolving strategies and latest evidence.

Induction of apoptosis by laminarin, regulating the insulin-like growth factor-IR signaling pathways in HT-29 human colon cells.

Weapons ovarian epithelial tumors may use in immune escape: an immunohistochemical correlational study.

Toll-like receptor 4 activation in cancer progression and therapy.

Similar Articles

CD95 ligand-expressing tumors are rejected in anti-tumor TCR transgenic perforin knockout mice.

Tumor counterattack: fact or fiction?

Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion?

Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back.

Partnerships & funding

Similar Articles

CD95 ligand-expressing tumors are rejected in anti-tumor TCR transgenic perforin knockout mice.
J Immunol, 166(5):3240-3247, 01 Mar 2001

Tumor counterattack: fact or fiction?

Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion?
Nat Med, 2(12):1361-1366, 01 Dec 1996

Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back.
J Immunol, 158(10):4521-4524, 01 May 1997

Search life-sciences literature (45,103,589 articles, preprints and more)

Tumor expression of Fas ligand (CD95L) and the consequences.

Author information

Affiliations

Authors

ORCIDs linked to this article

Abstract

Full text links

References

Citations & impact

Impact metrics

Citations of article over time

Alternative metrics

Article citations

Similar Articles

Partnerships & funding